New cholesterol-lowering ingredient
This article was originally published in The Tan Sheet
Executive Summary
Next Pharmaceuticals announces Dec. 5 its patented heart-health ingredient Flavoxine is clinically shown to increase HDL-cholesterol while "significantly reducing" LDL-cholesterol and triglycerides. The double-blind, placebo-controlled clinical trial included 80 subjects. "The active compounds from the plants used have been studied extensively and therefore Flavoxine does not have the risks frequently associated with new synthetic compounds," says Next Pharmaceuticals President and CEO Bob Garrison. The Carlsbad, Calif.-based company says Flavoxine is a blend of a proprietary extract of Phellodendron amurense and a patented extract of orange peel containing polymethoxylated flavones. The firm says the ingredient will be available to consumer product manufacturers in January...
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.